Genetic causes of human infertility

Endocrinology and Metabolism Clinics of North America

Volumn 32, Issue 3, 2003, Pages 549-572

  Layman, Laurence C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADOTROPIN; LEPTIN; LEPTIN RECEPTOR;

AUTOSOMAL DISORDER; CELL COMPARTMENTALIZATION; CHROMOSOME ABERRATION; CHROMOSOME DELETION Y; CLINICAL PRACTICE; CYSTIC FIBROSIS; FRAGILE X SYNDROME; GENE MAPPING; GENE MUTATION; GENETIC DISORDER; GENETICS; GONAD FUNCTION; HUMAN; HUMAN GENOME; INFERTILITY; PRIORITY JOURNAL; REVIEW;

EID: 0141733248     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(03)00040-9     Document Type: Review

References (97)

1. Layman LC. The molecular basis of human hypogonadotropic hypogonadism. Mol Genet Metab 1999;68:191-9.
2. Layman LC. The genetics of human hypogonadotropic hypogonadism. Am J Med Genet 1999;89:240-8.
3. Franco B, Guioli S, Pragliola A, et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991;353:529-36.
4. Legouis R, Hardelin J, Levilliers J, et al. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 1991;67:423-35.
5. Bick D, Franco B, Sherins RS, et al. Intragenic deletion of the KALIG-1 gene in Kallmann's syndrome. N Engl J Med 1992;326:1752-5.
6. Hardelin JP, Levilliers J, Blanchard S, et al. Heterogeneity in the mutations responsible for X chromosome-linked Kallmann syndrome. Hum Mol Genet 1993;2:373-7.
7. Rugarli EI, Lutz B, Kuratani SC, et al. Expression pattern of the Kallmann syndrome gene in the olfactory system suggests a role in neuronal targeting. Nat Genet 1993;4:19-26.
8. Rugarli E, Ballabio A. Kallmann syndrome from genetics to neurobiology. JAMA 1993;270:2713-6.
9. Duke VM, Winyard PJ, Thorogood P, Soothill P, Bouloux PM, Woolf AS. KAL, a gene mutated in Kallmann's syndrome, is expressed in the first trimester of human development. Mol Cell Endocrinol 1995;110:73-9.
10. Lutz B, Karatani S, Rugarli EI, et al. Expression of the Kallmann syndrome gene in human fetal brain and in the manipulated chick embryo. Hum Mol Genet 1994;3:1717-23.
11. Oliveira LM, Seminara SB, Beranova M, et al. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J Clin Endocrinol Metab 2001;86:1532-8.
12. Muscatelli F, Strom TM, Walker AP, et al. Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Nature 1994;372:672-6.
13. Zanaria E, Muscatelli F, Bardoni B, et al. An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 1994;372:635-41.
14. Zhang Y-H, Guo W, Wagner RL, et al. DAX1 mutations provide insight into structure-function relationships in steroidogenic tissue development. Am J Hum Genet 1998;62:855-64.
15. McCabe E. Disorders of glycerol metabolism. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular basis of inherited disease. 7th edition. New York: McGraw-Hill; 1995. p. 1631-52.
16. Habiby RL, Boepple P, Nachtigall L, Sluss PM, Crowley WF Jr, Jameson JL. Adrenal hypoplasia congenita with hypogonadotropic hypogonadism: evidence that DAX-1 mutations lead to combined hypothalmic and pituitary defects in gonadotropin production. J Clin Invest 1996;98:1055-62.
17. Guo W, Mason JS, Stone CG, et al. Diagnosis of X-linked adrenal hypoplasia congenita by mutation analysis of the DAX1 gene. JAMA 1995;274:324-30.
18. Achermann JC, Gu W-X, Kotlar TJ, et al. Mutational analysis of DAX1 in patients with hypogonadotropic hypogonadism or pubertal delay. J Clin Endocrinol Metab 1999;84: 4497-500.
19. Yu RN, Ito M, Saunders TL, Camper SA, Jameson JL. Role of Ahch in gonadal development and gametogenesis. Nat Genet 1998;20:353-7.
20. Montague CT, Farooqi S, Whitehead FP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903-8.
21. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998;18:213-5.
22. Clement K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998;392:398-401.
23. Weiss J, Crowley WF Jr, Jameson JL. Normal structure of the I gonadotropin-releasing hormone (GnRH) gene in patients with GnRH deficiency and idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989;69:299-303.
24. Weiss J, Adams E, Whitcomb RW, Crowley WF Jr, Jameson JL. Normal sequence of the gonadotropin-releasing hormone gene in patients with idiopathic hypgonadotropic hypogonadism. Biol Reprod 1991;45:743-7.
25. Layman LC, Wilson JT, Huey LO, Lanclos KD, Plouffe L Jr, McDonough PG. Gonadotropin-releasing hormone, follicle-stimulating hormone beta, and luteinizing hormone beta gene structure in idiopathic hypogonadotropic hypogonadism. Fertil Steril 1992;57:42-9.
26. Layman LC, Lanclos KD, Tho SPT, Sweet CR, McDonough PG. Patients with idiopathic hypogonadotropic hypogonadism have normal gonadotropin-releasing hormone gene structure. Adolesc Pediatr Gynecol 1993;6:214-9.
27. de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997;337: 1597-602.
28. Layman LC, Cohen DP, Jin M, et al. Mutations in the gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet 1998;18:14-5.
29. de Roux N, Young J, Brailly-Tabard S, Misrahi M, Milgrom E, Chaison G. The same molecular defects of the gonadotropin-releasing hormone determine a variable degree of hypogonadism in affected kindred. J Clin Endocrinol Metab 1999;84:567-72.
30. Caron P, Chauvin S, Christin-Maitre S, et al. Resistance of hypogonadotropic patients with mutated GnRH receptor genes to pulsatile GnRH administration. J Clin Endocrinol Metab 1999;84:990-6.
31. Beranova M, Oliveira LM, Bedecarrats GY, et al. Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2001;86:1580-8.
32. Cohen DP, Stein EM, Li Z, Matulis CK, Ehrmann DA, Layman LC. Molecular analysis of the gonadotropin releasing hormone receptor in polycystic ovarian syndrome. Fertil Steril 1999;72:360-3.
33. Kumar TR, Wang Y, Lu N, Matzuk MM. Follicle-stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat Genet 1997;15:201-4.
34. Matthews CH, Borgato S, Beck-Peccoz P, et al. Primary amenorrhea and infertility due to a mutation in the β-subunit of follicle-stimulating hormone. Nat Genet 1993;5:83-6.
35. Layman LC, Lee EJ, Peak DB, et al. Delayed puberty and hypogonadism caused by a mutation in the follicle stimulating hormone β-subunit gene. N Engl J Med 1997;337: 607-11.
36. Matthews C, Chatterjee VK. Isolated deficiency of follicle-stimulating hormone re-revisited. N Engl J Med 1997;337:642.
37. Layman LC, Porto AL, Xie J, et al. FSH beta gene mutations in a female with partial breast development and a male sibling with normal puberty and azoospermia. J Clin Endocrinol Metab 2002;87:3702-7.
38. Lindstedt G, Nystrom E, Matthews C, Ernest I, Janson PO, Chatterjee K. Follitropin (FSH) deficiency in an infertile male due to FSH beta gene mutation. A syndrome of normal puberty and virilization but underdeveloped testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations. Clin Chem Lab Med 1998;36:663-5.
39. Phillip M, Arbelle JE, Segev Y, Parvari R. Male hypogonadism due to a mutation in the gene for the b-subunit of follicle stimulating hormone. N Engl J Med 1998;338:1729-32.
40. Weiss J, Axelrod L, Whitcomb RW, Harris PE, Crowley WF Jr, Jameson JL. Hypogonadism caused by a single amino acid substitution in the β subunit of luteinizing hormone. N Engl J Med 1992;326:179-83.
41. Wu W, Cogan JD, Pfaffle RW, et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet 1998;18:147-9.
42. Cogan JD, Wu W, Phillips JA III, et al. The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. J Clin Endocrinol Metab 1998;83:3346-9.
43. Fofanova OV, Takamura N, Kinoshita E, et al. A mutational hot spot in the Prop-1 gene in Russian children with combined pituitary hormone deficiency. Pituitary 1998;1:45-9.
44. Dattani MT, Martinez-Barbera J-P, Thomas PQ, et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998;19:125-33.
45. Thomas PQ, Dattani MT, Brickman JM, et al. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet 2001;10:39-45.
46. Layman LC, Reindollar RH. The genetics of hypogonadism. Infertil Reprod Med Clin N Am 1994;5:53-68.
47. Layman LC, Reindollar RH. The diagnosis and treatment of pubertal disorders. Adolesc Med 1994;5:37-55.
48. Layman L. Familial ovarian failure. In: Lobo RL, editor. Perimenopause. New York: Springer Verlag; 1997. p. 46-77 [chapter 6].
49. Rao E, Weiss B, Fukami M, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997;16:54-63.
50. Belin V, Cusin V, Viot G, et al. SHOX mutations in dyschondrosteosis (Leri-Weill syndrome). Nat Genet 1998;19:67-9.
51. Shears DJ, Vassal HJ, Goodman FR, et al. Mutation and deletion of the pseudoautosomal gene SHOX cause Leri-Weill dyschondrosteosis. Nat Genet 1998;19:70-3.
52. Simpson JL, Rajkovic A. Ovarian differentiation and gonadal failure. Am J Med Genet 1999;89:186-200.
53. Bione S, Sala C, Manzini C, et al. A human homologue of the Drosophila melanogaster diaphenous gene is disrupted in a patient with premature ovarian failure: evidence for conserved function in oogenesis and implications for human sterility. Am J Hum Genet 1998;62:533-41.
54. Murray A. Premature ovarian failure and the FMR1 gene. Semin Reprod Med 2000;18:59-66.
55. Uzielli ML, Guarducci S, Lapi E, et al. Premature ovarian failure (POF) and fragile X premutation females: from POF to to fragile X carrier identification, from fragile X carrier diagnosis to POF association data. Am J Med Genet 1999;84:300-3.
56. Jager RJ, Anvret M, Hall K, Scherer G. A human XY female with a frame shift mutation in the candidate testis-determining gene SRY. Nature 1990;348:452-4.
57. Ostrer H. Sexual differentiation. Semin Reprod Med 2000;18:41-9.
58. Foresta C, Moro E, Ferlin A. Y chromosome microdeletions and alterations of spermatogenesis. Endocr Rev 2001;22:226-39.
59. Reijo R, Lee T-Y, Salo P, et al. Diverse spermatogenic defects in humans caused by Y chromosome deletions encompassing a novel RNA-binding protein gene. Nat Genet 1995;10:383-93.
60. Sun C, Skaletsky H, Birren B, et al. An azoospermic man with a de novo point mutation in the Y-chromosomal gene USP9Y. Nat Genet 1999;23:429-32.
61. Krausz C, Rajpert-de Meyts EW, Frydelund-Larsen L, Quintana-Muro L, McElreavey K, Skakkebaek NE. Double-blind Y chromosome microdeletion analysis in men with known sperm parameters and reproductive hormone profiles: microdeletions are specific for spermatogenic failure. J Clin Endocrinol Metab 2001;86:2638-42.
62. Dierich A, Sairam MR, Monaco L, et al. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci USA 1998;95:13612-7.
63. Aittomaki K, Lucena JLD, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic hypogonadism. Cell 1995;82:959-68.
64. Aittomaki K, Herva R, Stenman U-H, et al. Clinical features of primary ovarian failure caused by a point mutation in the follicle stimulating hormone receptor gene. J Clin Endocrinol Metab 1996;81:3722-6.
65. Beau I, Touraine P, Meduri G, et al. A novel phenotype related to partial loss of function mutations of the follicle stimulating hormone receptor. J Clin Invest 1998;102:1352-9.
66. Touraine P, Beau I, Gougeon A, et al. New natural inactivating mutations of the follicle-stimulating hormone receptor: correlations between receptor function and phenotype. Mol Endocrinol 1999;13:1844-54.
67. Tapanainen JS, Aittomaki K, Min J, Vaskivuo T, Huhtaniemi IT. Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility. Nat Genet 1997;15:205-6.
68. Gromoll J, Simoni M, Nieschlag E. An activating mutation of the follicle stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. J Clin Endocrinol Metab 1996;81:1367-70.
69. Whitney EA, Layman LC, Lanclos KD, Wall SW, McDonough PG. The follicle-stimulating hormone receptor gene is polymorphic in premature ovarian failure and normal controls. Fertil Steril 1995;64:518-24.
70. 566C-T) of the human follicle-stimulating hormone receptor gene in four populations using allele-specific hybridization and time-resolved fluorometry. J Clin Endocrinol Metab 1998;83:4338-43.
71. Simoni M, Gromoll J, Hoppner W, et al. Mutational analysis of the follicle-stimulating hormone (FSH) receptor in normal and infertile men: identification and characterization of two discrete FSH receptor isoforms. J Clin Endocrinol Metab 1999;84:751-5.
72. Kremer H, Kraaij R, Toledo SPA, et al. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. Nat Genet 1995;9:160-4.
73. Latronico AC, Anasti J, Arnhold IJP, et al. A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty. J Clin Endocrinol Metab 1995;80:2490-4.
74. Toledo SPA, Brunner HG, Kraaij R, et al. An inactivating mutation of the luteinizing hormone receptor causes amenorrhea in a 46,XX female. J Clin Endocrinol Metab 1996;81:3850-4.
75. Geissler WM, Davis DL, Wu L, et al. Male pseudohermaphroditism caused by mutations of testicular 17-beta-hydroxysteroid dehydrogenase 3. Nat Genet 1994;7:34-9.
76. Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5-alpha-reductase 2 gene in male pseudohermaphroditism. Nature 1991;354:159-61.
77. Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson ER. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci USA 1993;90:11673-7.
78. Bulun S. Aromatase deficiency and estrogen resistance: from molecular genetics to clinic. Semin Reprod Med 2000;18:31-9.
79. Jaaskelainen J, Tiitinen A, Voutilainen R. Sexual function and fertility in adult females and males with congenital adrenal hyperplasia. Horm Res 2001;56:73-80.
80. Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86:3070-8.
81. Yanase T, Simpson ER, Waterman MR. 17-Alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr Rev 1991;12:91-108.
82. Tajima T, Fujieda K, Kouda N, Nakae J, Miller WL. Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46, XY sex reversal and adrenal insufficiency. J Clin Endocrinol Metab 2001;86:3820-5.
83. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet 1997;17:393-8.
84. Consortium F-GA. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997;17:399-403.
85. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 1999;22:125-6.
86. Biason-Lauber A, Schoenle EJ. Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. Am J Hum Genet 2000;67:1563-8.
87. Pelletier J, Bruening W, Kashtan CE, et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991;67:437-47.
88. Barbaux S, Niaudet P, Gubler M-C, et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 1997;17:467-70.
89. Foster JW, Dominguez-Steglich MA, Guioli S, et al. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature 1994;372:525-30.
90. Imbeaud S, Belville C, Messika-Zeitoun L, et al. A 27 base-pair deletion of the antimullerian type II receptor gene is the most common cause of the persistent mullerian duct syndrome. Hum Mol Genet 1996;5:1269-77.
91. Olbrich H, Haffner K, Kispert A, et al. Mutations in DNAH5 cause primary ciliary dyskinesia and randomization of left-right asymmetry. Nat Genet 2002;30:143-4.
92. Umehara F, Tate G, Itoh K, et al. A novel mutation of desert hedgehog in a patient with 46,XY partial gonadal dysgenesis accompanied by minifascicular neuropathy. Am J Hum Genet 2000;67:1302-5.
93. Brown TR, Lubahn DB, Wilson EM, Joseph DR, French FS, Migeon CJ. Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: evidence for further genetic heterogeneity in this syndrome. Proc Natl Acad Sci USA 1988;85:8151-5.
94. Patterson MNH, Hughes IA, Gottlieb B, Pinsky L. The androgen receptor gene mutations database. Nucleic Acids Res 1994;22:3560-2.
95. Mercier B, Verlingue C, Lissens W, et al. Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 patients. Am J Hum Genet 1995;56:272-7.
96. Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332:1475-80.
97. Dode C, Levilliers J, Dupont JM, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 2003;33:463-5.